Lucid Capital analyst Elemer Piros initiated coverage of Unicycive Therapeutics (UNCY) with a Buy rating and $12 price target The company could launch oxylanthanum carbonate in the second half of 2025, one of the first innovative products in over a decade for the treatment of hyperphosphatemia, the analyst tells investors in a research note. The firm says Unicycive is building a “comprehensive” drug portfolio for chronic kidney disease and acute kidney injury.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- Buy Rating for Unicycive Therapeutics: Innovative Approach to Hyperphosphatemia Treatment with Oxylanthanum Carbonate
- Unicycive Therapeutics assumed with a Buy at H.C. Wainwright
- Unicycive Therapeutics Updates Annual Meeting Time
- Unicycive Therapeutics announces time change for FY25 annual meeting
- Buy Rating for Unicycive Therapeutics Driven by Strategic Positioning and Upcoming Regulatory Milestones
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue